Gurvinder Singh Rekhi, PhD - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gurvinder Singh Rekhi, PhD


Gurvinder Singh Rekhi, PhD
Director, R&D,
Elan Drug Delivery, Inc.

Gurvinder Singh Rekhi, PhD, is currently director of research and development at Élan Drug Inc. in Gainesville, Georgia, managing the activities of the formulation and analytical development, scale-up/transfer, and validation of controlled release dosage forms. He is responsible for regulatory submissions for three NDAs, and he represents the company in contract negotiations, scientific/technical presentations, and intellectual property.

Rekhi is currently an adjunct assistant professor of pharmaceutics at the University of Maryland, School of Pharmacy, as well as an associate professor at the Massachusetts College of Pharmacy. Rekhi also serves as an advisory board member for the Center for Drug Delivery Research at Mercer University, Southern School of Pharmacy.

Rekhi is a member of professional organizations, including the American Association of Pharmaceutical Scientists (AAPS), APhA, CRS, and Rho Chi Pharmaceutical Honor Society. He serves as an editorial board member of Pharmaceutical Technology and ad hoc reviewer for several pharmaceutical journals. He has served as a committee member on one MS, five PhD dissertations and directed two post-doctoral fellows. He has published and presented scientific papers in the US and at international conferences, and he holds numerous patents from the US Patent Office and several EU countries. He has co-authored chapters in the NABPLEX Pharmacy Review Book and the Handbook of Pharmaceutical Granulation Technology.

Rekhi received his B. Pharm. (1983) from Bombay College of Pharmacy, India. He obtained his MS (1986), BS (1989), and PhD (1991) degrees in Pharmaceutics and Industrial Pharmacy from Massachusetts College of Pharmacy. Rekhi is a registered pharmacist in the states of Connecticut, Maryland, and Georgia.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here